ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

LPX Lipoxen

7.875
0.00 (0.00%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lipoxen LSE:LPX London Ordinary Share GB00B08NWV55 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.875 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Lipoxen Share Discussion Threads

Showing 1201 to 1223 of 1450 messages
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
DateSubjectAuthorDiscuss
07/4/2011
00:58
Yes, it could be huge, but that's years down the road, and judging by the market's reaction, I'd say investors want to know what's going to pay Lipoxen's rent in the more immediate future.
123asd
07/4/2011
00:24
This by itself could be a 'game changer' for Lipoxen

IAVI collaboration update
Share this article
TIDMLPX

RNS Number : 2839E

Lipoxen PLC

05 April 2011

5 April 2011

Lipoxen plc

('Lipoxen' or the 'Company')

IAVI collaboration update

Lipoxen (AIM: LPX.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological, vaccines and siRNA delivery, announces that is has agreed an extension of the existing research agreement with the International Aids Vaccine Initiative (IAVI), the world's leading AIDS vaccine organization.

Based on data generated during the research phase of the original agreement, Lipoxen and IAVI have identified a vaccine formulation that, when used in a relevant preclinical model, induced antibodies which subsequently neutralised a number of different HIV strains when tested in the laboratory.

IAVI have extended the agreement which will now run until 30 September 2011. This will allow Lipoxen to create advanced versions of the candidate formulation and IAVI to undertake a repeat of the immunisation study to assess the efficacy of the refined vaccine.

Subject to the final results, Lipoxen and IAVI will jointly negotiate terms for the further development of any promising vaccine candidate.

Commenting on the extension, M. Scott Maguire, Chief Executive Officer of Lipoxen, said:

"The extension is a positive step and reflects the good antibody responses to our formulations. With more than 7,100 people a day infected with HIV there is strong demand for safe and effective vaccines for HIV and we hope that the extension will help us and IAVI take a step closer to developing a refined vaccine formulation that meets this need."

buywell2
05/4/2011
19:31
Thanks for posting.
"could be huge" - let's hope investors think so!

keeshond
05/4/2011
10:07
Very promising news - could be huge.
drewz
05/4/2011
09:53
Apologies if already seen ... ATB Weevie
weevie1978
23/3/2011
07:17
prelimanary results were on the 1st of april last year...
bobdown2
21/3/2011
22:48
Nice triangle formation building on the LPX chart

Supports move to 20p on good RNS news

Like signing up with a western partner for example re previous RNS testing results

buywell2
21/3/2011
14:00
Hopefully some news at last!
ak123
21/3/2011
13:37
onward and upward!
jsbach123
18/3/2011
22:58
Could be some contracts to be won with Japanese companies at this time
buywell2
18/3/2011
22:53
Looks like your post turned the stock back up again

Moving averages still look good.

Positive RNS news could send the stock back up to 20p


dyor

buywell2
18/3/2011
14:49
I bought some yesterday as they looked cheap given the earlier news a few months ago.

I think they're just catching up.Everybody should have a few of these I reckon.

ohisay
18/3/2011
10:22
spoke to soon....jumped up today..is there anything to this or had thjey just fallen to far..
bobdown2
17/3/2011
20:46
amonth since a post...a forgoton biotech...just giving it a post as it must be getting an inferiority complex..think you must try harder to get an rns out,
bobdown2
16/2/2011
16:19
I think the interview took place some time ago but is still available on the website of ProactiveInvestors.co.uk. You could tell how well a company is run judging from the man at the top.
richardwong78
16/2/2011
16:07
richardwong78........when you say 'after listening to the CEO's interview with Proactive Investors yesterday', do you mean the interview took place yesterday, (if so, is there a link anywhere), or do you mean you listened to an interview that was made a little while ago, yesterday?
duplicate book
16/2/2011
16:00
thanks rw78. maybe said interview itself has created a bit of todays interest.
bobdown2
16/2/2011
15:57
Two Wongs don't make it right :o))
duplicate book
16/2/2011
15:55
The bull point from a charting perspective is that not only is the share price in an up trend it is also above the short-term and long-term moving averages. The company is also fundamentally sound. After listening to the CEO's interview with Proactive Investors yesterday I could not resist in investing in this company.
richardwong78
16/2/2011
15:24
I hope you are right, Mr Wong.
drewz
16/2/2011
15:21
If you look at the chart the share price is at the beginning of a breakout. I expect it to go up to at least 20p.
richardwong78
16/2/2011
13:36
whoops. another tick up.
bobdown2
16/2/2011
13:32
some slightly larger buys than of late going through. will have to watch for an increase in activity.
bobdown2
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older

Your Recent History

Delayed Upgrade Clock